Immunomodulatory glycan LNFPIII alleviates hepatosteatosis and insulin resistance through direct and indirect control of metabolic pathways
about
Identifying the immunomodulatory components of helminthsSchistosome-Derived Molecules as Modulating Actors of the Immune System and Promising Candidates to Treat Autoimmune and Inflammatory DiseasesType 2 responses at the interface between immunity and fat metabolismA Neoglycoconjugate Containing the Human Milk Sugar LNFPIII Drives Anti-Inflammatory Activation of Antigen Presenting Cells in a CD14 Dependent PathwayIL-21 and IRF4: A complex partnership in immune and metabolic regulationHookworm infection is associated with decreased CD4+ T cell counts in HIV-infected adult Ugandans.FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.Helminth infections, type-2 immune response, and metabolic syndrome.Glycomic Analysis of Life Stages of the Human Parasite Schistosoma mansoni Reveals Developmental Expression Profiles of Functional and Antigenic Glycan MotifsA worm of one's own: how helminths modulate host adipose tissue function and metabolismHelminths, hygiene hypothesis and type 2 diabetes.Effect of Anthelmintic Treatment on Insulin Resistance: A Cluster-Randomized Placebo-Controlled Trial in Indonesia.Novel O-linked methylated glycan antigens decorate secreted immunodominant glycoproteins from the intestinal nematode Heligmosomoides polygyrus.The schistosoma granuloma: friend or foe?Galectins are human milk glycan receptorsHookworm excretory/secretory products induce interleukin-4 (IL-4)+ IL-10+ CD4+ T cell responses and suppress pathology in a mouse model of colitis.Mouse aldehyde-oxidase-4 controls diurnal rhythms, fat deposition and locomotor activityBlood spotlight on leukocytes and obesity.Immunomodulatory glycan lacto-N-fucopentaose III requires clathrin-mediated endocytosis to induce alternative activation of antigen-presenting cells.Lessons from helminth infections: ES-62 highlights new interventional approaches in rheumatoid arthritis.Priming dendritic cells for th2 polarization: lessons learned from helminths and implications for metabolic disorders.Aberrant immune response with consequent vascular and connective tissue remodeling - causal to scleroderma and associated syndromes such as Raynaud phenomenon and other fibrosing syndromes?Immunomodulation by helminths: Similar impact on type 1 and type 2 diabetes?Parasite excretory-secretory products and their effects on metabolic syndrome.Nematodes and human therapeutic trials for inflammatory disease.Surface expression patterns of defined glycan antigens change during Schistosoma mansoni cercarial transformation and development of schistosomula.The potential long-term effect of previous schistosome infection reduces the risk of metabolic syndrome among Chinese men.Praziquantel treatment after Schistosoma japonicum infection maintains hepatic insulin sensitivity and improves glucose metabolism in mice.Parasite-Derived Proteins for the Treatment of Allergies and Autoimmune Diseases.Foundations of Immunometabolism and Implications for Metabolic Health and Disease.Interleukin 10 and clustering of metabolic syndrome components in pediatrics.CAV1 Prevents Gallbladder Cholesterol Crystallization by Regulating Biosynthesis and Transport of Bile Salts.Immunomodulation by Helminths: Intracellular Pathways and Extracellular Vesicles
P2860
Q26823533-8078740A-2DB1-4D6F-BC2A-847F4C786A40Q28075563-8EB31FB8-A32F-466B-B633-5060E68ED3EDQ28082245-5CA8B7D7-924F-41EE-ACC6-1D314093BEE1Q28547758-77BFEB33-69F9-4448-8864-2E6630B750F2Q33646717-AD8451B1-F9BA-4CC2-ACFC-43973ACDFC75Q33773331-160B6ED5-DF53-4FFC-B237-79738DD7130EQ34366966-A3E1E131-CF41-4D11-9E93-5619A10A677DQ35200913-BFC78231-718A-4544-8203-318330F499BCQ35604915-4F1C50BC-22D8-4A9C-8F08-EF2CEE9BAFEFQ36052705-6FB2D7C3-224A-4B10-9706-8AFDFD771468Q36214734-BE82B873-380E-48B4-B834-758FBD6127D5Q36363419-FF4B9C80-209B-41AD-91C4-E5C3572C4CA4Q36647259-DDC7CBDB-588C-42BA-B1CC-B1C9CA5024A3Q36764281-E0EF3A1D-956C-4199-81C7-E3FD66A66304Q36843242-5A44C390-D40F-461A-883A-64B9E34A7288Q36911496-BA9D8230-3043-4EC3-BE75-A782BB87BBA8Q37125313-5E9BE684-D863-4582-90B4-A08D57422A4EQ37291602-726468E5-7844-4325-9B66-3F54D2FB8832Q37713387-4054730B-AF74-4C44-B091-71EC4847D868Q38199165-15FCB1F3-A912-46AF-BCBF-4D4947F3122CQ38264905-5A1DDB5E-9D3A-4E80-8509-77E714EB43B2Q38829051-A602588E-5F6F-46B8-98E8-384B1C449426Q39012899-30DF3E1D-BC0F-4465-9811-92D63F3F8F32Q39032609-8D6C42B7-AF6D-47C8-88A1-D439A67F378FQ39039247-AF4DB529-62A4-42C8-A83F-EFCBF8787459Q41011195-808BEA4D-86BE-4E1F-B847-0A55DEA4B417Q41384451-6326AF9A-6A27-4DC7-A6D2-DFD4BFA61F62Q42284439-58DD1D68-939A-4BAA-A6FA-FEC04AE69A3DQ45781393-3DDDB370-C820-4CA7-91A2-CE7A6883FF1FQ47772688-E943A286-E096-465D-A726-F8206DF4990CQ51327874-0D101C3A-E64B-416A-AF27-830F671F7B91Q53175255-9A6976CF-885F-41BB-97E4-B55FC16F426AQ58122562-2FBF721F-9975-435C-9166-FFE22637CB8F
P2860
Immunomodulatory glycan LNFPIII alleviates hepatosteatosis and insulin resistance through direct and indirect control of metabolic pathways
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Immunomodulatory glycan LNFPII ...... control of metabolic pathways
@ast
Immunomodulatory glycan LNFPII ...... control of metabolic pathways
@en
type
label
Immunomodulatory glycan LNFPII ...... control of metabolic pathways
@ast
Immunomodulatory glycan LNFPII ...... control of metabolic pathways
@en
prefLabel
Immunomodulatory glycan LNFPII ...... control of metabolic pathways
@ast
Immunomodulatory glycan LNFPII ...... control of metabolic pathways
@en
P2093
P2860
P356
P1433
P1476
Immunomodulatory glycan LNFPII ...... control of metabolic pathways
@en
P2093
Changlin Li
Chih-Hao Lee
Donald A Harn
Kristopher J Stanya
Lingling Dai
Matthew R Gangl
Prerna Bhargava
P2860
P2888
P304
P356
10.1038/NM.2962
P407
P50
P577
2012-10-28T00:00:00Z